Our Network of Consultants

My area of study is the intersection of clinical neuroscience, translational pharmacology, and computational biomarker discovery. I am a PhD candidate investigating how glymphatic and meningeal–lymphatic pathways relate to neuroinflammation in humans. I focus on immune-cell phenotyping and cell-free markers that may index inflammatory activity and neurodegenerative trajectories. Alongside sampling development, I contribute to assay and workflow optimisation for mass-spectrometry-ready proteomics, with an emphasis on automation, quality control, and reproducibility.

My pharmacology and drug-safety foundation was built through an MRes in Biological Science and Translational Medicine. I examined dose- and time-dependent paracetamol-induced kidney injury in renal cell models, differentiating apoptotic and necrotic mechanisms and linking experimental readouts to clinically relevant nephrotoxicity questions. I completed a systematic review on cilastatin as a renoprotective strategy and critically evaluated in vitro acute kidney injury models for translational validity. I also gained ward-level exposure as a Clinical Research Associate in nephrology, aligning laboratory findings with real-world clinical pathways and multidisciplinary decision-making.

From an industry and communications perspective, I have experience in medical affairs-adjacent work, including market analysis to support launch planning in an ophthalmic pharmaceutical company and the development of compliant training materials with medical teams. I have delivered conference and hospital presentations, tailoring complex findings to both clinical and public audiences, and I have completed structured projects on European compliance frameworks, which underpins my approach to regulatorily aware medical writing.

Computationally, I build end-to-end machine-learning workflows in Python and R for noisy, high-dimensional datasets, particularly proteomics and multimodal clinical data. My toolkit spans supervised learning, unsupervised clustering, and dimensionality reduction.

Overall, my expertise is translating complex biomedical and quantitative evidence into actionable deliverables, supported by an MBA in Clinical Leadership and a strong biochemistry foundation, including earlier research on TEX12 expression in somatic and cancer models.

Over 35 years experience in life science research and the life science tools industry. 25+ years experience as a senior corporate executive in leading public and private life science tools companies, as well as board service and consulting over the past 10 years. A primary focus has been in corporate development and merger & acquisition.

Specialties: corporate development, merger and acquisition, and strategic planning in the life science tools industry

Senior Life Sciences Executive and Technical Expert with 15+ years of experience driving innovation in biotechnology. Proven track record in building and scaling successful ventures, specializing in cell biology, automation, and AI-powered solutions. Currently serving as CEO of an iPSC technology company, while offering strategic consulting to emerging life science ventures.

Technical Expertise:
- Cell culture and cell line development (CLD)
- Extensive experience with cancer, CHO, HEK, cultured meat and iPSC cell lines
- Developing and validating automation and high-throughput AI-based imaging instrumentation
- Cell line optimization, immortalisation, engineering and characterization

Molecular & Synthetic Biology:
- Gene editing and genetic engineering
- Vector design and production
- Protein expression systems

Leadership Experience:
- Founded and scaled an iPSC quality control company from concept to market
- Led cross-functional teams of scientists, software engineers and engineers
- Developed and implemented automated laboratory workflows
- Successfully navigated multiple funding rounds and strategic partnerships

Industry Applications:
- Drug discovery and development
- Diagnostic platform development
- Viral vector manufacturing
- Stem cell technologies
- Vaccine development
- Recombinant protein production

Consulting Services:
- Strategic Planning
- Scientific advice
- Market entry strategy
- Technology road-mapping
- IP portfolio development
- Laboratory Operations
- Design and construction optimization
- Workflow automation

As a Professor of Chemistry at King's College London and Group Leader at the Francis Crick Institute, following nine years at Oxford University where I was also a Royal Society University Research Fellow, I bring over 20 years of experience at the intersection of biophysics, chemistry, and nanotechnology. My research has pioneered novel approaches in membrane biophysics and single-molecule detection, leading to fundamental breakthroughs in nanopore sensing technology. I have developed four patented innovations in this field, with three successfully licensed to industry partners, including methods that enable five-order magnitude improvements in DNA sequencing throughput.

My expertise spans single-molecule microscopy, membrane protein biophysics, microfluidics, and the development of artificial cell membrane systems. I've developed particular specialization in membrane protein function, interferometric scattering microscopy, and optical single-channel recording, contributing to over 70 peer-reviewed publications. This work has been recognized with multiple honors including election as a Fellow of the Royal Society of Chemistry and the RSC Norman Heatley Award.

As a regular reviewer for leading journals including Science and Nature, I maintain active engagement with cutting-edge developments across biophysics and nanotechnology. I've held appointments at Oxford, Stanford, and Cambridge universities, building a broad international network in academia and industry. My experience includes serving as an invited nominator for the Chemistry Nobel Committee, consulting for biotechnology companies, and maintaining successful research collaborations with leading biotech partners.

My technical knowledge spans patent disputes, particularly those involving biophysics and nanopore sensing technologies, complemented by extensive experience in technology commercialization and independent technical review.